| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
(-)-Menthyloxyacetic acid is a derivative of (-)-menthol, a well-known compound with a distinctive minty odor. As a chiral compound, it can be used as a chiral resolving agent for the separation of enantiomers. In biochemical contexts, (-)-menthyloxyacetic acid is a potential precursor in the biosynthesis of certain products and undergoes enzymatic conversion in some organisms. Its chiral nature allows it to interact stereospecifically with enzymes and biological targets. Further research is needed to identify its specific molecular targets and biological functions.
|
|---|---|
| ln Vitro |
In vitro studies of (-)-Menthyloxyacetic acid have focused on its role as a chiral resolving agent and research chemical. The compound's physical and chemical properties have been characterized, including its appearance as a white to off-white solid powder and density of 1.01 g/mL at 20°C. Its potential as a precursor in biosynthesis has been noted. These in vitro studies provide foundational data for understanding the compound's utility in chiral resolution and biochemical research.
|
| ln Vivo |
In vivo studies of (-)-Menthyloxyacetic acid are limited as the compound is primarily used as a research chemical and chiral resolving agent. As a derivative of (-)-menthol, it would be metabolized through standard xenobiotic pathways if administered. Its potential as a biosynthetic precursor suggests it may be involved in metabolic pathways in some organisms. However, comprehensive in vivo pharmacological studies specifically targeting this compound are not well documented in the available literature. The compound is intended for research use only and is not for human therapeutic use.
|
| Enzyme Assay |
In vitro enzyme assays for (-)-Menthyloxyacetic acid typically involve testing its properties as a chiral resolving agent. Chiral resolution is performed using chromatographic methods such as high-performance liquid chromatography with chiral stationary phases. The compound's purity and identity are assessed using analytical chemistry methods such as nuclear magnetic resonance spectroscopy and mass spectrometry. Its enzymatic conversion in biological systems may be studied using relevant enzyme assays. All assays are performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays for (-)-Menthyloxyacetic acid are limited as the compound is primarily used as a chiral resolving agent and research chemical rather than a biological agent. Its potential biological effects would be evaluated in the context of its use as a menthol derivative. Cells could be treated with varying concentrations of the compound and cell viability assessed using MTT or similar colorimetric assays. However, comprehensive cell-based studies specifically targeting (-)-Menthyloxyacetic acid are not well documented in the available literature.
|
| Animal Protocol |
In vivo animal experiments for (-)-Menthyloxyacetic acid are not well documented as the compound is primarily used as a research chemical and chiral resolving agent. For toxicology studies, animals may be administered the compound to evaluate its safety profile. Parameters assessed would include body weight, organ weights, and histopathology. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines. Comprehensive in vivo studies are not well documented in the available literature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of (-)-Menthyloxyacetic acid reflect its nature as a small chiral compound. It has a molecular weight of 214.30 and the molecular formula C12H22O3. The compound has a density of 1.01 g/mL at 20°C. As a derivative of (-)-menthol, it would be absorbed through the gastrointestinal tract and metabolized through standard xenobiotic pathways in the liver. Its chiral nature may influence its metabolism and pharmacokinetics. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (-)-Menthyloxyacetic acid has been evaluated in the context of its use as a research chemical. As a menthol derivative, it is expected to have a favorable safety profile at research concentrations. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile for pharmaceutical applications. The compound's menthol-derived structure suggests it may have low toxicity.
|
| References |
[1]. Luo X, et al. Enantiomeric resolution, thermodynamic parameters, and modeling of clausenamidone and neoclausenamidone on polysaccharide-based chiral stationary phases. Chirality. 2019 Jun;31(6):423-433. doi: 10.1002/chir.23068. Epub 2019 Apr 24.
|
| Additional Infomation |
(-)-Menthyloxyacetic acid (CAS# 40248-63-3) is also known as L-menthoxyacetic acid, (-)-menthoxyacetic acid, and L-p-menth-3-yloxyacetic acid. It has the molecular formula C12H22O3 and a molecular weight of 214.30. The compound appears as a white to off-white solid powder and has a density of 1.01 g/mL at 20°C. It is a derivative of (-)-menthol and can be used as a chiral resolving agent. In biochemistry, it is a potential precursor in biosynthesis. The compound is intended for research use only and is not for human therapeutic use.
|
| Molecular Formula |
C12H22O3
|
|---|---|
| Molecular Weight |
214.30
|
| Exact Mass |
214.157
|
| CAS # |
40248-63-3
|
| PubChem CID |
97814
|
| Appearance |
White to off-white solid powder
|
| Density |
1.01 g/mL at 20 °C(lit.)
|
| Boiling Point |
163-164 °C10 mm Hg(lit.)
|
| Melting Point |
52-55 °C(lit.)
|
| Flash Point |
>230 °F
|
| Index of Refraction |
n20/D 1.4672(lit.)
|
| LogP |
2.548
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
213
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])C(=O)O[H])[C@@]1([H])C([H])([H])[C@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]1([H])C([H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
CILPHQCEVYJUDN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H22O3/c1-8(2)10-5-4-9(3)6-11(10)15-7-12(13)14/h8-11H,4-7H2,1-3H3,(H,13,14)
|
| Chemical Name |
2-(5-methyl-2-propan-2-ylcyclohexyl)oxyacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6664 mL | 23.3318 mL | 46.6636 mL | |
| 5 mM | 0.9333 mL | 4.6664 mL | 9.3327 mL | |
| 10 mM | 0.4666 mL | 2.3332 mL | 4.6664 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
